vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TREX CO INC (TREX). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $161.1M, roughly 1.0× TREX CO INC). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -3.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -34.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Trex Company, Inc. is a manufacturer of wood-alternative composite decking, residential railing, and other outdoor items made from recycled materials. Its headquarters is in Winchester, Virginia.
ESPR vs TREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $161.1M |
| Net Profit | — | $2.3M |
| Gross Margin | — | 30.2% |
| Operating Margin | 50.6% | 2.2% |
| Net Margin | — | 1.4% |
| Revenue YoY | 143.7% | -3.9% |
| Net Profit YoY | — | -76.4% |
| EPS (diluted) | $0.32 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $161.1M | ||
| Q3 25 | $87.3M | $285.3M | ||
| Q2 25 | $82.4M | $387.8M | ||
| Q1 25 | $65.0M | $340.0M | ||
| Q4 24 | $69.1M | $167.6M | ||
| Q3 24 | $51.6M | $233.7M | ||
| Q2 24 | $73.8M | $376.5M | ||
| Q1 24 | $137.7M | $373.6M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | $-31.3M | $51.8M | ||
| Q2 25 | $-12.7M | $75.9M | ||
| Q1 25 | $-40.5M | $60.4M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | $-29.5M | $40.6M | ||
| Q2 24 | $-61.9M | $87.0M | ||
| Q1 24 | $61.0M | $89.1M |
| Q4 25 | — | 30.2% | ||
| Q3 25 | — | 40.5% | ||
| Q2 25 | — | 40.8% | ||
| Q1 25 | — | 40.5% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 39.9% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 45.4% |
| Q4 25 | 50.6% | 2.2% | ||
| Q3 25 | -11.4% | 24.7% | ||
| Q2 25 | 8.6% | 26.4% | ||
| Q1 25 | -34.0% | 24.0% | ||
| Q4 24 | -6.4% | 9.2% | ||
| Q3 24 | -31.0% | 23.2% | ||
| Q2 24 | 3.5% | 31.1% | ||
| Q1 24 | 52.5% | 31.9% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | -35.9% | 18.1% | ||
| Q2 25 | -15.4% | 19.6% | ||
| Q1 25 | -62.2% | 17.8% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | -57.2% | 17.4% | ||
| Q2 24 | -83.9% | 23.1% | ||
| Q1 24 | 44.3% | 23.8% |
| Q4 25 | $0.32 | $0.03 | ||
| Q3 25 | $-0.16 | $0.48 | ||
| Q2 25 | $-0.06 | $0.71 | ||
| Q1 25 | $-0.21 | $0.56 | ||
| Q4 24 | $-0.14 | $0.10 | ||
| Q3 24 | $-0.15 | $0.37 | ||
| Q2 24 | $-0.33 | $0.80 | ||
| Q1 24 | $0.34 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $3.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.0B |
| Total Assets | $465.9M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $3.8M | ||
| Q3 25 | $92.4M | $11.4M | ||
| Q2 25 | $86.1M | $5.5M | ||
| Q1 25 | $114.6M | $5.0M | ||
| Q4 24 | $144.8M | $1.3M | ||
| Q3 24 | $144.7M | $12.8M | ||
| Q2 24 | $189.3M | $1.2M | ||
| Q1 24 | $226.6M | $3.1M |
| Q4 25 | $-302.0M | $1.0B | ||
| Q3 25 | $-451.4M | $1.0B | ||
| Q2 25 | $-433.5M | $989.3M | ||
| Q1 25 | $-426.2M | $910.1M | ||
| Q4 24 | $-388.7M | $850.1M | ||
| Q3 24 | $-370.2M | $887.9M | ||
| Q2 24 | $-344.2M | $894.9M | ||
| Q1 24 | $-294.3M | $804.1M |
| Q4 25 | $465.9M | $1.5B | ||
| Q3 25 | $364.0M | $1.5B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.6B | ||
| Q4 24 | $343.8M | $1.3B | ||
| Q3 24 | $314.1M | $1.3B | ||
| Q2 24 | $352.3M | $1.3B | ||
| Q1 24 | $373.1M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $65.5M |
| Free Cash FlowOCF − Capex | — | $22.1M |
| FCF MarginFCF / Revenue | — | 13.7% |
| Capex IntensityCapex / Revenue | 0.0% | 26.9% |
| Cash ConversionOCF / Net Profit | — | 28.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | $134.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $65.5M | ||
| Q3 25 | $-4.3M | $196.9M | ||
| Q2 25 | $-31.4M | $249.8M | ||
| Q1 25 | $-22.6M | $-154.0M | ||
| Q4 24 | $-35.0M | $-8.5M | ||
| Q3 24 | $-35.3M | $132.8M | ||
| Q2 24 | $-7.2M | $193.7M | ||
| Q1 24 | $53.8M | $-174.0M |
| Q4 25 | — | $22.1M | ||
| Q3 25 | — | $142.9M | ||
| Q2 25 | — | $203.0M | ||
| Q1 25 | — | $-233.5M | ||
| Q4 24 | — | $-89.3M | ||
| Q3 24 | $-35.5M | $54.5M | ||
| Q2 24 | $-7.3M | $158.2M | ||
| Q1 24 | $53.8M | $-211.8M |
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | -68.7% | ||
| Q4 24 | — | -53.3% | ||
| Q3 24 | -68.7% | 23.3% | ||
| Q2 24 | -9.9% | 42.0% | ||
| Q1 24 | 39.0% | -56.7% |
| Q4 25 | 0.0% | 26.9% | ||
| Q3 25 | 0.0% | 18.9% | ||
| Q2 25 | 0.0% | 12.1% | ||
| Q1 25 | 0.0% | 23.4% | ||
| Q4 24 | 0.0% | 48.2% | ||
| Q3 24 | 0.3% | 33.5% | ||
| Q2 24 | 0.1% | 9.4% | ||
| Q1 24 | 0.1% | 10.1% |
| Q4 25 | — | 28.45× | ||
| Q3 25 | — | 3.80× | ||
| Q2 25 | — | 3.29× | ||
| Q1 25 | — | -2.55× | ||
| Q4 24 | — | -0.87× | ||
| Q3 24 | — | 3.27× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | 0.88× | -1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TREX
Segment breakdown not available.
